Simple Summary The diagnostic and clinical success of standardization of BCR-ABL1 p210
monitoring in chronic myeloid leukemia patients could be seen as a good example for …

[2] Didelot A., Kotsopoulos SK, Lupo A., Pekin D., Li X., Atochin I. Multiplex picoliter-droplet
digital PCR for quantitative assessment of DNA integrity in clinical samples. Clin Chem …

Minimal residual disease (MRD) assessment using peripheral blood instead of bone marrow
aspirate/biopsy specimen or the biopsy of the cancerous infiltrated by lymphoid …

Increasing evidence supports the prognostic significance of measurable residual disease
(MRD) in acute myeloid leukemia (AML). Dynamic MRD assessment for patients with AML …

Background/Aim: Droplet digital polymerase chain reaction (ddPCR) is an exact method of
measuring nucleic acids. The aim of this prospective study was to evaluate minimal residual …

Monitoring measurable residual disease (MRD) in acute myeloid leukemia (AML) plays an
important role in predicting relapse and outcome. The applicability of the leukemia-initiating …

Quantitative monitoring of BCR‑ABL1IS gene using reverse transcription quantitative‑PCR
(RT‑qPCR) is an important method for evaluating the treatment effects in patients with …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR::
ABL1 fusion gene, which results from a reciprocal translocation between chromosome 9 and …

Background Since the measurement of measurable residual disease (MRD) is part of
clinical routine examination for children affected with acute lymphoblastic leukemia (ALL) …

Historically, therapeutic drug monitoring (TDM) has mainly focused on measuring the level
of drugs and analyzing individualized pharmacokinetics. 1 However, during recent years …